Relay Therapeutics (RLAY) Interest Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Interest Expenses data on file, last reported at $365000.0 in Q1 2026.

• On a quarterly basis, Interest Expenses fell 59.93% year-over-year to $365000.0 in Q1 2026; TTM through Mar 2026 was $365000.0, a 59.93% decrease from a year earlier, with the FY2025 full-year figure at $480.5 million, up 11.25% from the prior year.
• Interest Expenses for Q1 2026 stood at $365000.0, up from $6000.0 in the prior quarter.
• Over the last five years, Interest Expenses for RLAY reached as high as $431.9 million in Q4 2024 and fell as low as $6000.0 in Q4 2025.
• Historically, Interest Expenses has averaged $28.6 million across 5 years, with a median of $1.3 million in 2024.
• Across the five-year window, Interest Expenses soared 164131.56% in 2024 and sank 100.0% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $7.6 million in 2022, then sank by 96.53% to $263000.0 in 2023, then surged by 164131.56% to $431.9 million in 2024, then sank by 100.0% to $6000.0 in 2025, then jumped by 5983.33% to $365000.0 in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $365000.0 in Q1 2026, $6000.0 in Q4 2025, and $239000.0 in Q3 2025.